Skip to main content
. 2023 Jan 3;15(1):169. doi: 10.3390/pharmaceutics15010169

Figure 4.

Figure 4

In vivo live imaging. (A) Representative live images of rats treated with P4 SLNs@DMNs at the skin of the back, abdomen, and ear. (BD) Average fluorescence intensity of rats treated with P4 SLNs@DMNs at the skin of the back, abdomen, and ear (n = 3). Data are expressed as mean ± SD. (E) The relative fluorescent intensity of rats treated with P4 SLNs@DMNs (n = 3). Data are expressed as mean ± SD. Note: ** denotes p < 0.01 vs. group of back, * denotes p < 0.05 vs. group of back. ## denotes p < 0.01 vs. group of abdomen. (F) The AUC0–t values and (G) T1/2 values of relative fluorescent intensity of rats treated with P4 SLNs@DMNs at the skin of the back, abdomen, and ear.

HHS Vulnerability Disclosure